/PRNewswire/ Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN).
ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer’s/Amyloid Field
Two positive events in January support PMN310 “best in class” positioning
TORONTO and CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its perspectives on recent progress in the Alzheimer’s field.
Two important events occurred in January 2021, both of which we consider very positive for the Alzheimer’s field, for the updated amyloid hypothesis, and for ProMIS Neurosciences. The FDA extended the PDUFA date (Prescription Drug User Fee Act) for review of Biogen’s aducanumab from March 7 to June 7, 2021, as announced on January 29. Lilly announced positive clinical results for their antibody, donanemab, on January 11, making it the
(2)
Two positive events in January support PMN310 best in class positioning
TORONTO and CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its perspectives on recent progress in the Alzheimer s field.
Two important events occurred in January 2021, both of which we consider very positive for the Alzheimer s field, for the updated amyloid hypothesis, and for ProMIS Neurosciences. The FDA extended the PDUFA date (Prescription Drug User Fee Act) for review of Biogen s aducanumab from March 7 to June 7, 2021, as announced on January 29. Lilly announced positive clinical results for their antibody, donanemab, on January 11, making it the third antibody with positive clinical results in Alzheimer s disease (AD) due to its targeting of aggr
ProMIS Neurosciences Inc.: ProMIS Neurosciences Announces Strategic Priorities for 2021
TORONTO and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today an outline of its strategic priorities and action plan for 2021.
The priorities for 2021 fall into four key areas:
Near term focus on rare neurodegenerative diseases, especially ALS
Use of proprietary platform to support portfolio expansion
PMN310 antibody lead program for Alzheimer s disease
COVID-19, further progress on serological assays
Rare disease. ProMIS has made significant progress in the rare disease field in 2020 and we plan to focus most of our R & D efforts in the near term on further advancing our programs selectively targeting toxic misfolded proteins